Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study
Authors' conclusion
ADA concentration correlates negatively with markers of inflammatory disease activity in RA, including IL-6. ADA concentration in the range 5 to 7 mg/L over the dose interval are associated with better disease control.
Study context
- Population
- People with rheumatoid arthritis (RA) receiving adalimumab for at least 4 weeks69.2% female
- Participants
- 156 people
- Exposure
- Adalimumab concentrations in DAS28 responders vs non-responders
- Outcome
- Adalimumab concentrations and their relation to patient characteristics, antidrug antibodies and disease activity
Methodological detailsobservational, multivariate general linear model
- Observational
- Multivariate general linear model
Main finding
As reported in the abstract
Adalimumab concentration by disease activity (DAS28)
P < 0.001
- Higher CRP independently associated with lower adalimumab concentrations (multivariate)
- P < 0.001
- Higher weight independently associated with lower adalimumab concentrations (multivariate)
- P < 0.004
Observational data: associations, not effects.
Further findings
Correlation between IL-6 and adalimumab concentrations (cytokine subgroup)
- Significant negative correlation, r
- −0.04
- P
- P < 0.01
Original publication
Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study. J Rheumatol. Published 15 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →